Pluripotent Stem Cell Technologies and Applications

Pluripotent stem cell technologies have revolutionised our capacity to study human development, model disease and advance regenerative medicine. Embryonic stem cells and induced pluripotent stem cells (iPSCs) share defining features of unlimited self-renewal and the potential to differentiate into any somatic cell type. Progress in reprogramming factors, culture conditions and epigenetic modulation has refined both naive and primed pluripotent states, improving genomic stability and differentiation fidelity. The advent of three-dimensional organoid systems, microfluidic platforms and biocompatible scaffolds has enabled in vitro recapitulation of organ architecture and cellular crosstalk. Moreover, genome editing technologies, high-throughput drug screening and single-cell profiling have extended the utility of PSCs in precision medicine and personalised therapeutics. Recent advances in direct reprogramming and transient epigenetic resetting strategies have further accelerated the generation of clinically relevant cell types, reducing tumourigenic risk and enhancing functional maturity. Collectively, these developments underscore the global significance of pluripotent stem cell research in modelling complex diseases, identifying novel drug targets and pioneering cell-based therapies that address unmet clinical needs.

Research from Nature Portfolio

Recent studies have unveiled a transient naive treatment (TNT) strategy that emulates the early embryonic epigenetic reset, effectively erasing donor-cell memory and aberrations in reprogrammed cells. This approach corrects residual repressive chromatin domains and CpH methylation, yielding iPSCs with epigenomes and differentiation efficiencies closely mirroring those of embryonic stem cells. Another significant advance has been the enhancement of cardiomyocyte generation via direct reprogramming of fibroblasts. It was shown that inhibition of pro-fibrotic signalling pathways markedly increases both the yield and maturation kinetics of induced cardiomyocytes, producing contractile cells in under two weeks. These findings refine our understanding of epigenetic regulation and signal-dependent barriers in pluripotent and direct cell conversion.

Pluripotent Stem Cell Technologies and Applications publication trend

The graph below shows the total number of articles in pluripotent stem cell technologies and applications across all publications each year (not limited to Nature Index journals).

Technical terms

Pluripotency: The capacity of a stem cell to differentiate into any cell type of the three embryonic germ layers.

Induced pluripotent stem cell: A somatic cell reprogrammed to a pluripotent state by defined transcription factors or chemical conditions.

Naive pluripotency: An early embryonic-like state of pluripotency characterised by broad differentiation potential and minimal epigenetic restrictions.

Epigenetic memory: Residual epigenetic marks from the donor cell that influence the behaviour and differentiation potential of reprogrammed cells.

Direct reprogramming: Conversion of one mature cell type into another without transitioning through a pluripotent intermediate state.

Organoid: A three-dimensional in vitro tissue model that self-organises to recapitulate key structural and functional features of an organ.

References

1. Transient naive reprogramming corrects hiPS cells functionally and epigenetically. Nature (2023).
2. High-efficiency reprogramming of fibroblasts into cardiomyocytes requires suppression of pro-fibrotic signalling. Nature Communications (2015).
3. Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications. Signal Transduction and Targeted Therapy (2024).
4. Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy. Molecular Cancer (2023).
5. Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proceedings of the Japan Academy Series B (2009).